<DOC>
	<DOCNO>NCT02203578</DOCNO>
	<brief_summary>This pilot clinical trial study romidepsin treat patient graft-versus-host disease ( GVHD ) respond treatment steroid . Romidepsin may effective treatment graft-versus-host disease cause bone marrow stem cell transplant .</brief_summary>
	<brief_title>Romidepsin Treating Patients With Steroid-Refractory Graft-versus-Host Disease</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine romidepsin developed therapy patient steroid-refractory GVHD . OUTLINE : Patients receive romidepsin intravenously ( IV ) 4 hour day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 6 month .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patients steroid ( immunosuppressive therapy [ IST ] ) refractory acute GVHD ( aGVHD ) chronic GVHD ( cGVHD ) Absolute neutrophil count &gt; = 750/mm^3 Platelet count &gt; = 50,000/mm^3 Corrected QT interval ( QTc ) = &lt; 480 msec Bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 x ULN Serum potassium &gt; = 3.8 mmol/L Serum magnesium &gt; = 1.8 mg/dL Serum creatinine = &lt; 2.0 mg/dl Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 03 Patients may undergo electrolyte repletion therapy meet eligibility requirement Patients must schedule tapering dos ( longer treat ) : Cyclosporine ; Tacrolimus ; Sirolimus ; Steroids ( patient may physiologic dos steroid ) Patients receive extracorporeal photopheresis must discontinue extracorporeal photopheresis place tapering schedule ; Any prior therapy GVHD must complete discontinued exception ; Patients breakpoint cluster region ( bcr ) ABL protooncogene 1 ( abl ) associate malignancy may tyrosine kinase inhibitor malignant disease therapy prophylaxis There must uncontrolled active infection medical condition investigator feel compromise safety treatment and/or assessment efficacy therapy The patient must aware high risk experimental nature treatment provide inform consent Negative serum pregnancy test time enrollment female childbearing potential For male female childproducing potential , use effective contraceptive method study least 6 month last dose romidepsin Active/uncontrolled infection Evidence relapse disease Life expectancy &lt; 12 week Pregnant breast feeding female Prior therapy romidepsin Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) ; patient seropositive hepatitis B virus vaccine eligible Any known cardiac abnormality : Congenital long QT syndrome QTc interval &gt; = 480 millisecond ; Myocardial infarction within 6 month course 1 , day 1 ( C1D1 ) ; subject history myocardial infarction 6 12 month prior C1D1 asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate ; Other significant electrocardiogram ( ECG ) abnormalities include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) ; Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian class IIIV ; patient doubt , patient stress image study , abnormal , angiography define whether CAD present ; An ECG record screen show evidence cardiac ischemia ( ST depression &gt; = 2 mm , measure isoelectric line ST segment ) ; doubt , patient stress image study , abnormal , angiography define whether CAD present ; Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) class II IV definition and/or ejection fraction &lt; 40 % multi gate acquisition ( MUGA ) scan &lt; 50 % echocardiogram and/or magnetic resonance imaging ( MRI ) ; A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause ; Any cardiac arrhythmia require antiarrhythmic medication ( exclude stable dos betablockers ) Uncontrolled hypertension , i.e. , blood pressure ( BP ) &gt; = 160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion ; Patients take drug lead significant QT prolongation must ECG prior treatment Concomitant use cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor Concomitant use medication know induce disulfiramlike reaction alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>